Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
norden.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
Moin! Dies ist die Mastodon-Instanz für Nordlichter, Schnacker und alles dazwischen. Folge dem Leuchtturm.

Administered by:

Server stats:

3.6K
active users

norden.social: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.7

#sublineages

0 posts0 participants0 posts today
Giuseppe Michieli<p>Neutralizing <a href="https://mstdn.science/tags/Activity" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Activity</span></a> and Viral <a href="https://mstdn.science/tags/Escape" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Escape</span></a> of <a href="https://mstdn.science/tags/Pemivibart" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Pemivibart</span></a> by <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>SARS</span></a>-CoV-2 <a href="https://mstdn.science/tags/JN1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>JN1</span></a>&nbsp;<a href="https://mstdn.science/tags/sublineages" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>sublineages</span></a></p><p>Source: BioRxIV, AbstractPemivibart (Pemgarda/VYD222) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on March 22, 2024, for COVID-19 pre-exposure prophylaxis in immunocompromised individuals. However, its efficacy and resistance against JN.1 sublineages have yet to be fully characterized. Here, we first assessed the neutralizing…</p><p><a href="https://etidioh.wordpress.com/2024/11/11/neutralizing-activity-and-viral-escape-of-pemivibart-by-sars-cov-2-jn1-sublineages/" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">etidioh.wordpress.com/2024/11/</span><span class="invisible">11/neutralizing-activity-and-viral-escape-of-pemivibart-by-sars-cov-2-jn1-sublineages/</span></a></p>
Giuseppe Michieli<p><a href="https://mstdn.science/tags/Pemivibart" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Pemivibart</span></a> is less active against recent <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>SARS</span></a>-CoV-2 <a href="https://mstdn.science/tags/JN1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>JN1</span></a> <a href="https://mstdn.science/tags/sublineages" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>sublineages</span></a> <a href="http://biorxiv.org/cgi/content/short/2024.08.12.607496v1?rss=1" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">http://</span><span class="ellipsis">biorxiv.org/cgi/content/short/</span><span class="invisible">2024.08.12.607496v1?rss=1</span></a> </p><p>Pemivibart neutralized both JN.1 and <a href="https://mstdn.science/tags/KP2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>KP2</span></a> in vitro with comparable activity, whereas its potency was decreased slightly against <a href="https://mstdn.science/tags/LB1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>LB1</span></a>, <a href="https://mstdn.science/tags/KP23" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>KP23</span></a>, and <a href="https://mstdn.science/tags/KP3" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>KP3</span></a> but substantially against <a href="https://mstdn.science/tags/KP311" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>KP311</span></a>. Critically, the 50% inhibitory concentration of pemivibart against KP.3.1.1 was ~6 g/mL, or ~32.7 fold higher than that of JN.1.</p>
ExploreLive feeds
About